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This study describes variation in the time interval between surgery and radiotherapy in breast cancer
(BC) patients and assesses factors at patient, hospital and radiotherapy centre (RTC) level inﬂuencing this
variation. To do so, the factors were investigated in BC patients using multilevel logistic regression. The
study sample consisted of 15,961 patients from the Netherlands Cancer Registry at 79 hospitals and 19
(RTCs) with breast-conserving surgery or mastectomy directly followed by radiotherapy. The percentage
of patients starting radiotherapy 42 days varied from 14% to 94%. Early year of incidence, higher age,
higher stage, mastectomy, higher ASA category and no availability of radiotherapy facilities were
signiﬁcantly associated with a longer time interval between radiotherapy and surgery. More patients
received radiotherapy 42 days in hospitals with on-site radiotherapy facilities (OR 1.36, p ¼ 0.024).
Among the remainder, signiﬁcant variation was found at the RTC level (11.1%, s2 ¼ 0.254, SE 0.054), and
at the hospital level (6.4% s2 ¼ 0.443, SE 0.163) (ICC 0.064). The signiﬁcant delay and unexplained
variance remaining at the RCT and hospital level suggests delays caused by the patient referral pathway
from hospital to RCT, and indicates potential for improvement at both levels.
© 2015 Elsevier Ltd. All rights reserved.Introduction
Breast cancer (BC), on which surgery is performed in all 91
hospitals in the Netherlands, is the most common type of cancer
among women in the country, with more than 14,500 new cases
diagnosed in 2014. The ﬁrst national evidence based breast cancer
treatment guideline, developed in 2002 and revised and expanded
thereafter, states that radiotherapy is considered an integral part of
breast-conserving treatment. After mastectomy, radiotherapy is
administered in high-risk cases and is also considered in cases with
an intermediate risk of loco regional recurrent disease [1]. In bothnter The Netherlands (IKNL),
þ31 88 2345500; fax: þ3188
t@iknl.nl (M. Gort), j.jobsen@
Maduro), h.struikmans@
uikmans), s.siesling@iknl.nlsettings, the aim of adjuvant radiotherapy is to reduce the risk of
local recurrent disease as well as the risk of distant metastases.
In the past 20 years, due to the rising incidence of cancer and
indications for radiotherapy treatment [2e4], demand for it has
increased. While in some countries the capacity of radiotherapy
facilities has not increased, resulting in increasingly long delay
[5,6], in the Netherlands the existing lack of capacity in 2000 was
addressed and resolved by 2009e2011 [7]. However, the impres-
sion in the Netherlands still remains that interval times between
surgery and start of radiotherapy are long.
In 2011, the National Breast Cancer Organization the
Netherlands (NABON) deﬁned a multidisciplinary set of BC quality
indicators. Most of these describe the care process in terms of
treatment given according to the guideline and the timeliness of
treatment. One of the process indicators is the indicator for adju-
vant radiotherapy. This concerns the time interval between the last
therapeutic surgical procedure and the start of postoperative
radiotherapy, and is deﬁned as the percentage of patients starting
radiotherapy 42 days after their surgery [8].
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hospitals as well as factors inﬂuencing this time interval has not yet
been studied. Insight into these factors could provide directions for
improvement. This study therefore aims to describe variation in
this time interval and to assess the factors inﬂuencing this interval
at patient, hospital and radiotherapy centre (RTC) level.
Patients and methods
Study population
This study was performed in 79 hospitals (8 academic, 49 gen-
eral and 22 top clinical hospitals) and 19 RTCs in the Netherlands in
the period 2009e2011. The hospitals cover the diagnoses and
treatment of about 85% of all BC patients. BC patients were selected
from the nationwide population-based Netherlands Cancer Regis-
try (NCR). All data has been obtained from patient ﬁles in the
hospitals by trained registration assistants and coded according to a
national manual. Patient, tumour and treatment characteristics are
registered. Topography and morphology are coded according to the
(ICD-0-3) and staging according to the TNM classiﬁcation 7th Edi-
tion [9,10]. Since 2011, in addition to the NCR data, more detailed
data has been gathered for the NABON Breast Cancer Audit.
Patient selection for this study was according to the NABON
indicator deﬁnition. From the NCR, all female patients diagnosed
with invasive or non-invasive (DCIS) BC without distant metastases
who underwent either breast conserving surgery (BCS) or mas-
tectomy with postoperative radiotherapy during the period
2009e2011 were included irrespective of their neo-adjuvant
therapy or adjuvant hormone and/or chemotherapy after radia-
tion. Since the Dutch guidelines does not recommend a speciﬁc
sequence of radiotherapy and chemotherapy, and as the NABON
guideline speciﬁes, we excluded patients who received adjuvant
chemotherapy before radiotherapy (n ¼ 16,269). Patients treated
with intra-operative radiotherapy (n¼ 139) and patients for whom
the RTC was unknown (n ¼ 169) were excluded, resulting in a total
of 15,961 BC patients for study.
Deﬁnition of timing of postoperative radiotherapy
Timing of postoperative radiotherapy was according to NABON
indicator, namely time from last therapeutic surgery until start of
radiotherapy. For patients with axillary lymph node dissection, the
date of the axillary dissection was deﬁned as last surgery. The time
interval was categorized into two categories: 42 days and >42
days.
Measures
The inﬂuence of factors on the interval between surgery and
start of radiotherapy was determined at three levels: patient, hos-
pital and RTC. At patient level, the variables considered were age,
tumour stage and type of surgery. For 2011, palpability, multi-
focality, type of radiotherapy and ASA scorewere also available. The
American Society of Anesthesiologists (ASA) physical status clas-
siﬁcation system was used to assess the ﬁtness of patients before
surgery. ASA category 1 includes healthy patients (32%), ASA cate-
gory 2 includes patients with severe diseases (45%), ASA category 3
includes patients with serious illness (ASA-score 3 and 4) (6%).
Variables at hospital level were hospital volume, type of hospital
and availability of an on-site radiotherapy facilities. The volume of a
hospital was deﬁned as the number of BC surgeries in 2011. Hos-
pitals were divided into <100 BC surgeries (n ¼ 21), 100-200 sur-
geries (n¼ 39) andmore than 200 surgeries (n¼ 19) on average per
year. The type of hospital, deﬁned by the hospital where the last
therapeutic surgical intervention was conducted, was divided intothree categories: academic hospital (n ¼ 8), general hospital
(n ¼ 49) and top clinical hospital (n ¼ 22). Academic hospitals are
directly related to an university, involved in education of medical
students and focussed on research. Both academic and top clinical
hospitals provide medical training to surgical residents. In addition,
hospitals were grouped into hospitals with on-site radiotherapy
facilities (maximum distance of 1 km of the hospital) and hospitals
without radiotherapy facilities. RTCswere classiﬁed as independent
RTC (n ¼ 6), department of a top clinical hospital (n ¼ 6) and
department of an academic hospital (n ¼ 7).
Data analysis
Differences between the hospitals are represented as funnel
plots with two-sigma limits as deﬁned by formula by Spiegelhalter
[11]. To test between-group differences for 42 days and >42 days,
c2 tests were used. Multilevel logistic approach was used to eval-
uate the inﬂuence of factors associated with time from surgery to
start of radiotherapy. This was applied because multilevel analysis
takes into account the hierarchical structure of the data and pro-
vides more accurate estimates than traditional regression analysis
[12]. The BC patients were nested into hospitals and RTCs. The
dependent variable was dichotomized according to the 42 days
norm. First, the dataset of patients diagnosed in 2009e2011 was
analysed (n ¼ 15,961). Next, for a subgroup that included all pa-
tients diagnosed in 2011, an additional analysis was performed
including the available variables ASA category, multifocality, type of
radiotherapy and palpability (n ¼ 6495).
In the ﬁrst stage of the analysis, a null model without any var-
iables was estimated. This model estimates which part of total
variance in the dependent variable, timing of radiotherapy, can be
assigned to different levels. Next, univariate analysis with a
threshold for inclusion of a P-value ¼ 0.10 was performed. Multi-
level variable logistic regression analysis with factors signiﬁcantly
related to a time interval of 42 days was performed. Patients,
hospital and RTC characteristics that were signiﬁcant in the uni-
variate analysis were added stepwise into the model. The effects of
different variables upon the likelihood of receiving radiotherapy
42 days were expressed in odds ratios (OR) with 95% conﬁdence
intervals (CI) andwere obtained from the b coefﬁcient and standard
error of themodel (OR¼ EXP b). The size of the variance of a level in
combination with standard error (SE) was used as a rough test to
judge the signiﬁcance of the variance. The intra class correlation
coefﬁcient (ICC) estimated dependency of observations within a
certain level [13].
Since in logistic multilevel analysis the lowest level variance is
ﬁxed to the variance of a logistic distribution with a variance of p2/
3, the unexplained variance of the radiotherapy and hospital level
can only be interpreted as a proportion of the total unexplained
variance [14].
For the multivariable analysis, P-values were considered sig-
niﬁcant at 0.05. Stata version 12.0 was used for all analyses.
Results
Study population
Table 1A presents the patient characteristics, and Table 1B
shows the hospital and RTC characteristics together with the per-
centage of patients with radiotherapy 42 days and >42 days after
surgery. Of the total number of BC patients 68% received radio-
therapy 42 days. This improved over time, from 61%  42 days in
2009, to 70% patients in 2011. The median number of days between
last surgery and start of radiotherapy was 38 days (interquartile
range 32e46 days). Furthermore, 90% received radiotherapy 56
Table 1A
Patient characteristics and percentage of patients having radiotherapy 42 days after surgery, for the period 2009e2011 and 2011.
Characteristics 2009e2011 P-value 2011 P-value
42 days, n ¼ 10,790 (%) >42 days,
n ¼ 5171(%)
42 days




2011 4548 (42.2) 1947 (37.7)
2010 3465 (32.1) 1453 (28.1) <0.001
2009 2777 (25.7) 1771 (34.2)
Age
<50 2054 (19.0) 1145 (22.1) 836 (18.4) 409 (21.0)
50e59 3338 (30.9) 1447 (28.0) 1358 (29.9) 500 (25.7)
60e69 3214 (29.8) 1428 (27.6) <0.001 1396 (30.7) 542 (27.8) <0.001
70e79 1916 (17.8) 961 (18.6) 825 (18.1) 400 (20.6)
>80 268 (2.5) 190 (3.7) 133 (2.9) 96 (4.9)
Stage (pTNM)
DCIS 1436 (13.3) 581 (11.2) 572 (12.6) 217 (11.2)
I 6269 (58.1) 2275 (44.1) 2598 (57.0) 834 (42.8)
II 2372 (22.0) 1569 (30.3) <0.001 1055 (23.2) 567 (29.1) <0.001
III 693 (6.4) 731 (14.1) 317 (7.0) 324 (16.6)
Unknown 20 (0.2) 15 (0.3) 6 (0.1) 5 (0.3)
Multifocal
No 4164 (91.6) 1677 (86.1)
Yes 384 (8.4) 270 (13.9) <0.001
ASA category
1 1559 (34.3) 540 (27.7)
2 2091 (46.0) 844 (43.4) <0.001
3 227 (5.0) 142 (7.3)
Unknown 671 (14.7) 421 (21.6)
Palpability
No 2035 (44.7) 734 (37.7)
Yes 2416 (53.2) 1163 (59.7) <0.001
Unknown 97 (2.1) 50 (2.6)
Type of surgery
Breast conserving surgery 9774 (90.6) 4152 (80.3) 4094 (90.0) 1517 (77.9)
Mastectomy 1016 (9.4) 1019 (19.7) <0.001 454 (10.0) 430 (22.1) <0.001
Type of radiotherapy
Breast/chest wall with boost 2411 (53.0) 939 (48.2)
Breast/chest wall without boost 1525 (33.5) 622 (31.9)
Breast/chest wall þ with boost regional 205 (4.5) 107 (5.5) <0.001
Breast/chest wall þ without boost regional 312 (6.9) 223 (11.5)
Other 6 (0.1) 6 (0.3)
Unknown 89 (2.0) 50 (2.6)
Fig. 1. Funnel plot with percentage radiotherapy 42 days after surgery, for breast
cancer patients by hospital.
S. Katik et al. / The Breast 24 (2015) 468e475470days and 99% 84 days. The tertiles showed a signiﬁcant difference
for incidence year, age, stage, multifocality, ASA category, palpa-
bility, type of surgery, type of radiotherapy, Hospital of radio-
therapy facilities and type of radiotherapy centre.
Patients
A large percentage of the patients (77%) had stage I or stage II BC.
The majority underwent breast-conserving surgery (87%). A
smaller percentage of patients had radiotherapy after surgery 42
days in case of early year of incidence, higher age, higher stage, a
multifocal tumour, a palpable tumour, a higher ASA category,
mastectomy and radiotherapy on the breast and chest wall without
boost (Table 1A). Of the patients, 47% received adjuvant radio-
therapy only, 46% received a combination of adjuvant radiotherapy,
hormone therapy and/or chemotherapy, 3% received neo-adjuvant
hormone and/or chemotherapy and adjuvant radiotherapy, and 4%
received neo-adjuvant hormone and/or chemotherapy and adju-
vant radiotherapy, hormone therapy and/or chemotherapy after
radiotherapy.
Hospitals
Of the patients, 49% were operated in general hospitals, 42% in
top clinical hospitals, and 9% in academic hospitals. About a quarter
of the hospitals (27%) performed less than 100 surgeries on average
per year, and 73% performed more than 100. The majority (77%) ofthe hospitals had no on-site radiotherapy facilities (Table 1B). The
percentage of patients with radiotherapy starting 42 days after
surgery varied between hospitals (n ¼ 79) from 14% to 94%. The
variation in the time interval across hospitals over the period
2009e2011 is over-dispersed, on the basis of the two-sigma crite-
rion, 22 hospitals were low-outlier and 25 hospitals were high-
outlier (Fig. 1). Patients who underwent their treatment in hospi-
tals with on-site radiotherapy facilities more frequently started
radiotherapy 42 days after surgery (Table 2).
Table 1B
Hospital and RTC characteristics.
42 days,









General Hospital 5201 (48.2) 2556 (49.4) 2235 (49.1) 948 (48.7)
Top clinical Hospital 4588 (42.5) 2160 (41.8) 0.298 1873 (41.2) 832 (42.7) 0.273
Academic Hospital 1001 (9.3) 455 (8.8) 440 (9.7) 167 (8.6)
Hospital surgical volume
<100 1651 (15.3) 766 (14.8) 713 (15.7) 307 (15.8)
100e200 4551 (42.2) 2241 (43.4) 0.363 1964 (43.2) 845 (43.4) 0.974
>200 4588 (42.5) 2164 (41.8) 1871 (41.1) 795 (40.8)
Hospital of radiotherapy facilities
No RT facilities 7174 (66.5) 3697 (71.5) 3068 (67.5) 1444 (74.2)
On-site RT facilities 3616 (33.5) 1474 (28.5) <0.001 1480 (32.5) 503 (25.8) <0.001
Type of radiotherapy centre
Department of Academic Hospital 4630 (43.0) 2641 (51.1) 1947 (42.8) 995 (51.1)
Department of Top clinical Hospital 2562 (23.7) 1279 (24.7) <0.001 1081 (23.8) 439 (22.6) <0.001
Independent centre 3598 (33.3) 1251 (24.2) 1520 (33.4) 513 (26.3)
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About 46% of the patients had radiotherapy in a radiotherapy
department of an academic hospital (Table 1B).
Within the same RTC, there was a large variance in time to
start radiotherapy amongst the hospitals (Fig. 2). For example,
the radiotherapy department of academic hospital ‘AC 2’ had
patients from a hospital where 13% received treatment 42 days
(minimum) and patients from a hospital where 63% received
treatment 42 days (maximum). The variation withinTable 2
























Top clinical Hospital 1.17 (0.93e1.48)






No RT facilities 1
On-site RT facilities 1.26 (0.98e1.63)
Type of radiotherapy centre
Department of Academic Hospital 1
Department of Top clinical Hospital 1.08 (0.52e2.25)
Independent centre 1.69 (0.82e3.48)
OR, odds ratio; 95% CI, 95% conﬁdence interval; RT, radiotherapy.
a Threshold P < 0.10.
b Statistically signiﬁcant (P < 0.05).independent RTCs and departments of top clinical hospitals was
comparable. The variation was largest for hospitals that referred
patients to the radiotherapy department of an academic hospital
(Fig. 2).
Multilevel analysis
First, a null model was generated, revealing the variance at each
level. The null model for the period 2009e2011, without any
explanatory variables, showed that 11.0% of the variance could begery (2009e2011).
Multivariable logistic regressionb


























Fig. 2. Box plots with percentage radiotherapy 42 days after surgery for hospitals by RTCs.
S. Katik et al. / The Breast 24 (2015) 468e475472attributed to the RTC level and 6.7% to the hospital level. Both the
variance of the hospital level and the variance of the RTC level were
statistically signiﬁcant (s2 ¼ 0.247, SE 0.053; s2 ¼ 0.435, SE 0.159).
Table 2 shows the results of the univariate analysis and multivari-
able analysis for 2009e2011.
In the null model for 2011, of the total variances, 8.6%
(s2¼ 0.338, SE 0.142) were at the RTC level, and 8.0% (s2¼ 0.317, SE
0.083) at hospital level. Variances on both levels were statistically
signiﬁcant. Table 3 shows the results of the univariate analysis and
multivariable analysis for 2011.Patient factors
In the univariate model for 2009e2011 (Table 2), incidence year,
age, stage and type of surgery were associated with radiotherapy
42 days. In the multivariate model, these variables remained
signiﬁcant. Compared to cases diagnosed in 2011, patients diag-
nosed in 2009 were less likely to receive radiotherapy 42 days
after surgery (OR 0.59, 95% CI 0.54e0.64). Patients older than 80
years (OR 0.75, 95% CI 0.60e0.94), patients with advanced stage III
(OR 0.44, 95% CI 0.38e0.52), and patients who underwent mas-
tectomy (OR 0.66, 95% CI 0.58e0.76), were signiﬁcantly less likely to
receive radiotherapy 42 days after surgery.
Additional analysis for patients in 2011 (Table 3) shows that,
besides the variables mentioned above, multifocality, ASA category,
type of radiotherapy and palpability were associated with radio-
therapy 42 days after surgery in the univariate model. In the
multivariatemodel, the ASA category remained signiﬁcant. Patients
with ASA category 3 were less likely to receive radiotherapy 42
days after surgery (OR 0.57, 95% CI 0.43e0.74). Patient factors
including age, stage and type of surgery also remained factors with
signiﬁcant inﬂuence on the likelihood of receiving radiotherapy
42 days after surgery. This was comparable to the results of the
multivariable analysis of the data of 2009e2011.Hospital factors
Of the hospital factors, only availability of radiotherapy facilities
was associated with radiotherapy time interval in the univariate
model (p ¼ 0.074). In the multivariable analyses, this variable
remained signiﬁcant when adjusted for other factors. Patients who
underwent surgery in hospitals with on-site radiotherapy facilities
were more likely to have radiotherapy 42 days compared topatients treated in hospitals without radiotherapy facilities (OR
1.36, 95% CI 1.04e1.77).
RTC factors
In univariate analysis, the type of RTC had no signiﬁcant effect
on the time interval of receiving radiotherapy after surgery
(p ¼ 0.320).
Multilevel analyses full model
Including the signiﬁcant patient and hospital factors into the full
model (Table 2), the factors signiﬁcantly associated with the time
interval between radiotherapy and surgery were year of incidence,
age, stage, type of surgery, ASA category and availability of radio-
therapy facilities. Of the remaining variation, signiﬁcant unex-
plained variation was at the RTC level (11.1%, s2 ¼ 0.254, SE 0.054)
and the hospital level (6.4% s2 ¼ 0.443, SE 0.163) (ICC 0.064). This
unexplained variation indicates as yet undeﬁned factors at hospital
and RTC level.
Discussion
This population-based study in the Netherlands among 79
hospitals and 19 RTCs shows a large inter-hospital and inter-RTC
variation in the time interval between surgery and start of radio-
therapy in BC patients in the period 2009-2011. This study exam-
ined the factors that inﬂuence the indicator timing of adjuvant
radiotherapy set by NABON: the percentage of patients receiving
radiotherapy 42 days after surgery. In 68% of the patients in our
study (n¼ 15,961), this was achieved. An increase in the percentage
was observed over the years, from 61% in 2009 to 70% in 2011. This
improvement over time is likely to be the result of the actions
enabling transparency, particularly with respect to waiting times
[15]. In 90% of the patients, radiotherapy started 56 days. This
corresponds well with the international guideline of EUSOMA,
which recommends that patients without chemotherapy receive
radiotherapy within 8 weeks [16]. The variances between hospitals
and RTCs found in this study are in line with previous reports
[17e19].
Several factors at patient, hospital and RTC level inﬂuenced
whether patients received radiotherapy 42 days. The patient
factors stage and type of surgery were found to be most dominant
Table 3
Multilevel logistic regression with odds ratios of having radiotherapy 42 days after surgery (2011).
Univariate logistic regressiona P-Value Multivariable logistic regressionb P-Value
OR (95% CI) OR (95% CI)
Age <0.001a 0.023b
<50 0.73 (0.62e0.86) 0.84 (0.70e1.00)
50e59 1 1
60e69 0.96 (0.82e1.12) 0.95 (0.81e1.12)
70e79 0.73 (0.61e0.86) 0.79 (0.66e0.94)
>80 0.45 (0.33e0.61) 0.69 (0.50e0.96)
Stage (pTNM) <0.001a <0.001b
DCIS 0.85 (0.71e1.03) 0.85 (0.70e1.03)
I 1 1
II 0.53 (0.46e0.61) 0.58 (0.49e0.67)
III 0.27 (0.22e0.32) 0.37 (0.28e0.50)
X 0.36 (0.10e1.34) 0.39 (0.10e1.47)
Multifocal <0.001a 0.386
No 1 1
Yes 0.61 (0.51e0.74) 0.91 (0.75e1.12)
ASA category <0.001a <0.001b
1 1
2 0.84 (0.73e0.96) 0.88 (0.76e1.02)
3 0.48 (0.37e0.61) 0.57 (0.43e0.74)
Unknown 0.90 (0.72e1.13) 1.00 (0.79e1.27)
Palpability <0.001a 0.332
No 1 1
Yes 0.73 (0.65e0.82) 1.08 (0.94e1.25)
Unknown 0.72 (0.50e1.05) 0.85 (0.58e1.26)
Type of surgery <0.001a <0.001b
Breast conserving surgery 1 1
Mastectomy 0.34 (0.29e0.40) 0.54 (0.42e0.70)
Type of radiotherapy <0.001a 0.144
Breast/chest wall with boost 1 1
Breast/chest wall without boost 0.89 (0.78e1.02) 1.07 (0.92e1.24)
Breast/chest wall þ with boost regional 0.69 (0.53e0.90) 1.10 (0.83e1.47)
Breast/chest wall þ without boost regional 0.45 (0.37e0.56) 1.52 (1.13e2.03)
Other 0.31 (0.10e1.03) 0.91 (0.26e3.14)
Unknown 0.79 (0.53e1.18) 1.16 (0.76e1.76)
Type of hospital 0.604
General Hospital 1
Top clinical Hospital 1.00 (0.74e1.34)





Hospital radiotherapy facilities 0.019a 0.011b
No RT facilities 1 1
On-site RT facilities 1.44 (1.06e1.96) 1.52 (1.10e2.10)
Type of radiotherapy centre 0.651
Department of Academic Hospital 1
Department of Top clinical Hospital 1.01 (0.50e2.07)
Independent centre 1.35 (0.68e2.70)
OR, odds ratio; 95% CI, 95% conﬁdence interval; RT, radiotherapy.
a Threshold P < 0.10.
b Statistically signiﬁcant (P < 0.05).
S. Katik et al. / The Breast 24 (2015) 468e475 473factors on patient level. Patients with pathological stage II and III
disease waited longer to receive radiotherapy than patients with
stage I. This latter ﬁnding corresponds with those of another
population-based study in which the investigators found shorter
waiting times for patients with stage I [20]. Patients who under-
went mastectomy were more likely to receive radiotherapy >42
days after surgery. This may be due to differences in post-surgery
complications and a longer recuperation time of mastectomy. As
in Bouche et al. [21], a signiﬁcant lower likelihood of older patients
receiving radiotherapy 42 days was found. This corresponds with
Struikmans et al. [4], who found that increasing age was associated
with a reduced use of radiotherapy.
Overall, this study reveals a large variation in time to start
radiotherapy among hospitals and RTCs. Patients who underwentsurgery in hospitals with on-site radiotherapy facilities, irrespective
of the type of operating hospital, were more likely to receive
radiotherapy 42 days after surgery. The largest variation was
between hospitals that referred patients to the radiotherapy
department of an academic hospital. After adjustment in the
multivariable analysis for patient factors and hospital factors,
variation between hospitals and RTCs remained signiﬁcant, sug-
gesting an inﬂuence of both hospitals and RTCs. This unexplained
variance at hospital and RTC level indicates that there may be other
factors that were not taken into account in this study, and this re-
quires additional research.
An important factor for variation in timing is likely to be the
differences in organization of care between hospital and RTCs.
At RTC level, the time interval between surgery and start of
S. Katik et al. / The Breast 24 (2015) 468e475474radiotherapy is not fully explained by the type of centre. In Ash [22],
the major contributors to delay on RTC level were limitations in
capacity, and Van Lent et al. [23] found that several factors could be
associated with longer time intervals: high workload (patients
treated per staff member), long access times and a high number of
patients treated per linear accelerator (per standard working hour).
Since there are different working strategies for RTCs in the
Netherlands, strategies concerning information transfer and
scheduling procedures, this may inﬂuence waiting times. In the
Netherlands, some patients are invited based on the planned date
of operation, some immediately after the tumour board, which is
mandatory for all BC patients in the Netherlands, and, in other
cases, the departments await a formal referral with complete
documentation. On the basis of our study, further research should
examine in detail the effect of capacity, workload and information
transfer on waiting times.
At hospital level, the organization of tumour boards may inﬂu-
ence the time interval through sequences in pre-treatment imaging
and consultation with other specialists [24]. For example, in Dutch
hospitals there are differences in the frequencies of the meetings of
the tumour boards. These can vary from between twice aweekwith
a special board for BC only, to once a week for all tumours. In
addition, in some hospitals without on-site radiotherapy facilities,
radiotherapy consults are available in the outpatient department.
Further research is needed to explore whether information transfer
and scheduling patients are better organized in these situations,
and how this inﬂuences the timing of radiotherapy.
Published evidence about the optimal time interval and
treatment efﬁcacy is contradictory. Some studies have shown
that patients with longer waiting times for radiotherapy have an
increased risk of local recurrence [25e27]. However, Livi et al.
[28] note that timing of radiotherapy itself does not affect local
recurrence, but prognostic factors do. A corresponding study by
Jobsen et al. [29] found that a time interval of more than 112 days
had no negative effect on local control. In another study, Jobsen
et al. [30], found a signiﬁcant negative effect for survival in
starting radiotherapy shortly after surgery (1e36 days) and sur-
vival beneﬁt for starting radiotherapy after 36 days for patients
with breast conserving surgery (n ¼ 1473). Besides, interaction
between combinations of therapies could confound the effect of
delay in radiotherapy.
The present study has a number of strengths and limitations.
The main strength lies in the large size of the study population for
which data was complete and gathered from patient ﬁles in a
standardized manner. Another strength of this study is that infor-
mation was collected at patient, hospital and RTC level. It was
therefore possible to examine the share of each level of the total
variance, and which factors at each level were related to the start of
adjuvant radiotherapy 42 days after surgery. The study is, how-
ever, limited, especially at RTC level, because the availability of
detailed explanatory RTC factors was limited. It was therefore un-
able to explain which factors inﬂuenced the variance on RTC level.
On the other hand, this study provides clear insight into the vari-
ation in timing amongst hospitals and RTCs, and provides data
useful for analysing time intervals in further studies.
In conclusion, this population based study reports large var-
iations in time between surgery and start of adjuvant radio-
therapy between hospitals and RTCs in BC patients in the
Netherlands. After adjustment of patient factors and hospital
factors, unexplained variance on RTC and hospital level remained
signiﬁcant. This suggests delays caused by the patient referral
pathway from hospital to RCT, and indicates possibilities for
improvement. Further research should examine underlying cau-
ses at both hospital and RCT level.Funding
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